What is Elpiscience?
Founded in 2017 and headquartered in Shanghai, China, Elpiscience is dedicated to the innovation and development of cutting-edge cancer immunotherapies. The company operates within the biopharmaceutical sector, focusing on translating scientific discoveries into effective therapeutic solutions for patients battling various forms of cancer. Its clinical-stage status suggests a robust pipeline of drug candidates undergoing rigorous testing and validation.
How much funding has Elpiscience raised?
Elpiscience has raised a total of $225M across 3 funding rounds:
Series A
$20M
Series B
$100M
Series C
$105M
Series A (2017): $20M with participation from Lilly Asia Ventures
Series B (2019): $100M led by Hyfinity Investments
Series C (2021): $105M supported by Maison Capital, Cormorant Asset Management, Pluto Connection Limited, Greater Bay Area Homeland Development Fund, and Superstring Capital
Key Investors in Elpiscience
Maison Capital
Maison Capital is an investment firm that emphasizes long-term perspectives, in-depth research, and independent thinking, focusing on creating wealth and improving quality of life. They are involved in various investment activities and have a dedicated research team.
Cormorant Asset Management
Cormorant Asset Management is a prominent life sciences investment firm driven by a deep focus on fundamental scientific principles, providing financial resources to support innovative publicly traded and private companies in biotech and allied sectors.
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm focused on becoming a trusted partner for entrepreneurs seeking smart capital to build great companies developing breakthrough products that treat diseases and improve human health.
What's next for Elpiscience?
With its latest major strategic investment, Elpiscience is poised to accelerate its research and development initiatives, potentially advancing its pipeline of cancer immunotherapies through critical clinical trials. The significant enterprise-level funding indicates a strategic focus on scaling operations, expanding its research capabilities, and potentially preparing for future commercialization efforts. This capital infusion is expected to bolster Elpiscience's position in the competitive biopharmaceutical landscape, enabling further exploration of novel therapeutic targets and enhancement of its existing treatment platforms.
See full Elpiscience company page
